Objective:
The article reviews clinical evidence, practical considerations, and sustainability benefits of dropless cataract surgery as an alternative to postoperative eye-drop regimens.
Approach:
- Kaiser Permanente Northern California study: A retrospective comparative-effectiveness cohort study examined approximately 69,800 eyes treated from 2018 through 2021. It compared topical prednisolone acetate, with or without an NSAID, with subconjunctival triamcinolone acetonide (Kenalog) at 10 mg/mL or 40 mg/mL, given in low (1.0–3.0 mg) or high (3.1–5.0 mg) doses.
- Optegra Eye Health Care study: A study of more than 15,000 patients compared dropless cataract surgery with a standard postoperative medication pathway. The supplied article excerpt does not include the study’s outcome results.
Key Findings:
- In the Kaiser Permanente study, high-dose Kenalog 10 mg/mL (approximately 4 mg) was associated with 36% lower odds of postoperative macular edema than topical prednisolone acetate, with similar odds of glaucoma events and rebound iritis.
- Adding an NSAID to prednisolone acetate had outcomes comparable to prednisolone alone. Kenalog 40 mg/mL groups had statistically significantly higher odds of glaucoma events.
- The Optegra comparison found no statistically significant difference in cystoid macular edema (3.1% dropless vs 3.3% drops) or intraocular pressure spikes (0.60% vs 0.68%).
- The presenters described reduced eye-drop packaging, prescribing, dispensing, storage, and waste as sustainability advantages of dropless care.
Interpretation:
The presenters characterized subconjunctival triamcinolone with intracameral antibiotic prophylaxis as an alternative to postoperative drops. They advised caution for patients younger than 65, those with glaucoma or ocular hypertension, ocular herpetic infection, or axial length greater than 29 mm, citing increased risk of steroid-related intraocular pressure spikes.
Limitations:
- The Kaiser Permanente evidence was retrospective and excluded patients with prior ocular surgery or chronic conditions such as uveitis.
- Dr. Chandra noted that the study findings were specific to brand-name Kenalog, as brands may differ in particle shape and size and exhibit different pharmacodynamics.
Conclusion:
The presenters reported comparable outcomes between dropless and traditional drop pathways in the Optegra comparison, alongside patient-convenience and sustainability advantages.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.